BERKELEY HEIGHTS, N.J., Nov. 15 /PRNewswire-FirstCall/ -- Genta Incorporated released findings from the initial clinical dosing of G4544, the Company's proprietary small molecule that is intended as a treatment for diseases associated with accelerated bone loss.

BERKELEY HEIGHTS, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Genta Inc. announced that the Food and Drug Administration (FDA) has allowed the Investigational New Drug (IND) exemption that was submitted by the Company for its new drug known as G4544.

BERKELEY HTS., N.J. and TARRYTOWN, N.Y., Aug. 1 /PRNewswire-FirstCall/ -- Genta Inc. and Emisphere Technologies, Inc. jointly announced today the submission of an Investigational New Drug Exemption (IND) to the Endocrinologic and Metabolic Drugs Division of the U.S.

BERKELEY HEIGHTS, N.J., March 2 /PRNewswire-First